Loading...
01/10 18:21
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings report shows strong financial performance with a 13% EPS growth, a 21% increase in operating earnings, and robust cash flow. The share repurchase program indicates confidence in the company's stock. Despite flat revenue, adjusted figures show significant growth. The Q&A reveals resilience against macroeconomic factors and effective cost management. However, management's lack of clarity on some issues slightly tempers optimism. Overall, the positive financial metrics and strategic share repurchase outweigh the concerns, suggesting a positive stock price movement.
Earnings Per Share (EPS) $2.35, growth of 13% year-over-year, driven by strong operating earnings growth of 21% and contributions from all five operating segments.
Total Company Revenue Nearly $55 billion, flat on a reported basis, but increased 19% year-over-year when adjusting for customer contract expiration, driven by strong demand across pharma and growth businesses.
Gross Profit Dollars Increased by 10% year-over-year, reflecting strong operating leverage despite a 4% increase in SG&A.
Operating Earnings Increased by 21% year-over-year, supported by strong performance in the pharmaceutical segment and cost control efforts.
Pharmaceutical Segment Revenue $50.4 billion, relatively flat, but increased 20% year-over-year when excluding customer contract expiration, driven by brand and specialty pharmaceutical sales.
Pharmaceutical Segment Profit $662 million, growth of 14% year-over-year, driven by contributions from brand and specialty products and positive generics program performance.
GMPD Segment Revenue Increased 2% to $3.2 billion, driven by volume growth from existing customers.
GMPD Segment Profit Increased to $39 million, driven by cost optimization initiatives.
Cash Position $3.3 billion at the end of the quarter.
Adjusted Free Cash Flow $1.2 billion year-to-date, with expectations to be at the high end of prior guidance range of approximately $1.5 billion.
Share Repurchases $750 million during the year, with an average price of $117 per share.
Interest and Other Expenses Increased by $38 million to $65 million, primarily due to acquisition-related financing costs.
Effective Tax Rate 22.4%, a 2.5 point increase from the prior year due to the non-repetition of positive discrete items.
Average Diluted Shares Outstanding 240 million shares, 2% lower than a year ago due to share repurchase efforts.
Other Segment Revenue Increased 13% year-over-year, with profit growth of 22% to $134 million.
Acquisition of Advanced Diabetes Supply Group (ADSG): Completed the acquisition of ADSG at the beginning of April, expected to be slightly accretive to EPS immediately.
Expansion in Specialty Care: GI Alliance's recent acquisitions, including Urology America and Potomac Urology, mark an expansion into urology, enhancing the multi-specialty model.
New Customer Onboarding: Successful onboarding of Publix during the quarter, contributing to revenue growth.
Market Positioning in Pharmaceuticals: Pharmaceutical revenue increased 20% excluding customer contract expiration, driven by brand and specialty pharmaceutical sales growth.
Growth in Other Segments: Other businesses reported revenue growth of 17% to 19%, driven by organic growth and contributions from ADSG.
Operational Efficiencies in GMPD: GMPD segment profit increased due to cost optimization initiatives and a focus on Cardinal Health branded products.
Investment in U.S. Manufacturing: Invested approximately $7 billion in the U.S. over the last two years, enhancing domestic manufacturing and distribution capabilities.
Strategic Focus on Specialty and Pharmaceuticals: Continued focus on specialty care and pharmaceuticals as key growth areas, with expectations for strong growth in fiscal year 2026.
Mitigation of Tariff Impacts: Proactive measures taken to mitigate tariff impacts, including increasing U.S. manufacturing capacity and diversifying supplier networks.
Regulatory Issues: Cardinal Health is proactively monitoring proposed legislation and regulation, indicating potential risks associated with changes in healthcare regulations that could impact operations.
Supply Chain Challenges: The company acknowledges the reliance on an efficient global supply chain and has faced challenges due to tariffs and regulatory actions, particularly affecting the GMPD segment.
Economic Factors: The macroeconomic environment is described as increasingly complex, which poses risks to operational execution and financial performance.
Competitive Pressures: The company faces competitive pressures in the healthcare market, necessitating continuous adaptation and strategic execution to maintain its market position.
Tariffs: The company anticipates $200 million to $300 million in gross tariff costs in fiscal '26, which could impact profitability despite mitigation efforts.
Customer Contract Expiration: The expiration of customer contracts has affected revenue growth, necessitating strategic adjustments to maintain performance.
Acquisition Integration Risks: The integration of recent acquisitions, such as GI Alliance and Integrated Oncology Network, presents operational challenges that could impact financial results.
Investments in U.S.: Approximately $7 billion invested in the last two years in the U.S., including acquisitions, expanded domestic manufacturing, and technology.
Acquisitions: Completed acquisition of Advanced Diabetes Supply Group in April, and positive early performance from GI Alliance and Integrated Oncology Network.
Growth in Specialty and Nuclear: Continued strong performance in Specialty and Nuclear segments, with significant growth in Theranostics.
Operational Improvements: Focus on operational execution and cost optimization in GMPD segment.
Customer Onboarding: Successful onboarding of Publix, contributing to revenue growth.
EPS Guidance: Raised fiscal year 2025 EPS guidance to a range of $8.05 to $8.15.
Free Cash Flow Guidance: Expecting adjusted free cash flow at the high end of prior guidance, approximately $1.5 billion.
Pharma Segment Profit Growth: Raising segment profit guidance for Pharma to 11.5% to 12.5% growth.
GMPD Segment Profit Guidance: Narrowing guidance for GMPD to $130 million to $140 million.
Revenue Growth in Other: Expecting fiscal year 2025 revenue growth of 17% to 19% in Other segment.
Fiscal Year 2026 Outlook: Expecting robust cash flow generation and double-digit non-GAAP EPS growth.
Share Repurchase Program: Cardinal Health repurchased $750 million in shares during the year, completing $375 million of accelerated share repurchases in March. The average price of year-to-date share repurchases was $117 per share.
The earnings report shows strong financial performance with a 13% EPS growth, a 21% increase in operating earnings, and robust cash flow. The share repurchase program indicates confidence in the company's stock. Despite flat revenue, adjusted figures show significant growth. The Q&A reveals resilience against macroeconomic factors and effective cost management. However, management's lack of clarity on some issues slightly tempers optimism. Overall, the positive financial metrics and strategic share repurchase outweigh the concerns, suggesting a positive stock price movement.
The earnings call presents a mixed but overall positive outlook. Despite a 4% revenue decrease due to customer transition, organic growth is strong at 15%. EPS growth is solid at 9%, and gross margins have improved. Share repurchase and dividend plans are robust, and specialty business growth is promising. However, raw material shortages and economic factors pose risks. The Q&A reveals confidence in handling these challenges, with management raising guidance due to strong demand. The positive aspects outweigh the negatives, suggesting a positive stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
